Philip Morris
the Cetus Story
Fields
- Type
- REPT, OTHER REPORT
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Named Person
- Cohen, S.N.
- Glaser, D.
- Request
- Stmn/R1-004
- Stmn/R1-150
- Named Organization
- Cetus
- Stanford
- Litigation
- Stmn/Produced
- Site
- R37
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- xei84e00
Document Images
The Cetus Story
(As Presented to Potential Clients)
lcgical innovation - the commercial exploitation of molecular biology.
Cetus Corporation~is the leading exemplification of a dramatic techno--
Cetus Corporation was founded in 1971 to bring a new level of scientific
y4';y Y .. .
'"`~-V ~ intensity to industrial microbiolo
~~~~ gy. Its very creation~was a harbinger..
~'YLx * '.
r~~ ~ In the since then, many of our
years predictions have proven conserva °
tive. Cetus has built a solid record of accomplishments of immediate
.l_..- . 4.~., . 3r
economic impact. Beginning with programs of massive screening for drug
companies, Cetus today serves several large clients in diverse major
industries, and simultaneously carries out internal programs building
proprietary technology for its own account.
1 ^1r 'Z~!
~..
Most important, the Cetus
team is multi-disciplinary and experienced.
Using incomparable facilities, Cetus scientists are well-qualified to.;~
address the broad challenge - the industrial application of all develop=
developments in recombinant DNA technology. All Cetus work in this, as
limited to an unmatched investment in and capability to implement all
ments in molecular biology. This includes, but is not in any way
in all other fields, is carried out solely in Cetus facilities and
grandstanding and quick profit, and fraught with ethical questions.
eschew paper or phantom financial arrangements clearly designed for
our investment must not be compromised by questionable "deals." We
totally financed by Cetus. This reflects our corporate philosophy that
Scientific Background
.. , .. _ .._ . .. -~ . . . ~~. .. , .. .. .. .. - - .. . .. ~~
...
i.'f.
?
.
0
The purpose of all programs in industrial microbiology is to harness the `~ :f2
metabolic machinery of microorganisms. There are innumerable different
kinds of microorganisms; there may be as much variety in the microbial
~'.~.
world as in all other forms of life combined. Only a very few specific
members of this enormous group have been harnessed by man, starting in
prehistoric times: the fermentation of cheeses, beer and wines and the`~
leavening of bread are microbial processes. So are the ravages of
infection, unfortunately the most familiar manifestations of microbial I'A
activity. Ironically, the epidemics which decimated mankind until this
generation are now largely controlled by another family of microbial
products: antibiotics.
Exploiting microbial processes for the benefit of man has been more an
art than a science; only in recent years have we seen the beginnings of
serious attempts to mount truly scientific efforts in this area. By
comparison with the enormity of the problem, these efforts are typically
small in scope and maddeningly inefficient in execution.
T.P enumerate those few familiar examples of successful industrial..,,.,
utilization of microorganisms runs the risk of short-changing the real
potential of the concept in its broadest sense.
N
N `s
A
r } . - . .. ... ~,, a. _- . ~.:._
-" ' ' .. .. - .. . .. . .,. 5~l . - 3:
.
f ~.
,; ., . .. _. :..
... . ~~... -. -.. . ... ~.r s. ~.:,
. . . .. ., ~~ - ~~..., . . ~. ~~ ~_

When we exploit a particular microorganism, it is because we have dis-
covered that as that organism carries out the intricate metabolic pro-
i.e., when it facilitates a useful reaction.-'.
ganism becomes useful to man when a particular gene becomes useful,
cell to make a particular enzyme. In turn, each~enzyme facilitates a
particular reaction, i.e., produces a particular product. A microor-
portion of the DNA molecule) contains the "instructions" causing the
protein molecule called an enzyme. Typically, each gene (a certain
vidual biochemical reaction is facilitated by a biochemical catalyst -
As is true for all living things, the "blueprint" for these complex
metabolic processes resides in the genetic molecule DNA. Each indi-
cesses which comprise its finely-tuned life mechanisms, one or more of
these metabolic processes accomplish something useful to man as well.
capabilities.. Cetus' first contribution to industrial microbiology :
Cetus has developed and utilizes a unique combination of technological
~ .:.: . ~~~:- ~ ~. ~ .~~.
`.. 1 . ..... : .~ - ~. . ~ ~- . " . 1 ~~. ,,.t , .-.~. ..~.ti ~
involved massive screening of microorganisms. This work arose out of
the genetic development of microorqanisms with preciselv those charac=
. 1,. ,.-,~
garding detection of rare events. This permits us to efficiently manage_;
Nobel laureate Professor Donald Glaser's inspiration and insight re-;-1
conversion of wood into sugar, or the production by fermentation of
teristics which are suited to an important task, whether that be the
chemicals to replace scarce petrochemical feedstocks.
To put this in perspective, we should ask - how do new useful genes
appear, and how are they discovered?
microorganisms have come to man's attention in all the years in which he
selection." Small wonder that such a small number of truly useful
"fittest" in the Darwinian sense: they lose out in subsequent compe-
tition with their non-mutant,cousins, and are eliminated by "natural
properties which are useful to man, but they turn out not to be the
difficult to discover these "improvements." They may be enhanced for
,.,
is an improvement observed. But another factor makes it even more
microorganism. Only rarely, perhaps once in 10,000 surviving mutants,
These changes have the effect of changing the instructions, thus af-
fecting the enzymes and the corresponding metabolic reactions. Most
such changes (mutations) are deleterious and many are fatal to the
From time to time, and especially during the process of reproduction,
when DNA molecules undergo duplication, minute changes occur in the DNA.
has been looking!
ment programs undertaken by drug companies manufacturing antibiotics.
In a few selected instances, industry has embarked on systematic genetic
improvement programs. A useful example: the so-called strain improve-
as 100 organisms daily. If a desired improvement occurs once in 10,000
Laborious techniques are necessary; a typical company may screen as many
teresting enhancement, say, of antibiotic yield, the rewards are indeed
increment, and several must be parlayed to achieve economically in-
progeny, the lesson is clear: an improvement will be seen once every
U0 working days. Since each improvement may represent only a slight
slow in coming.
~ ~+~~.i,;
4.~

f~,
_ ~~1
u v1~~
4
-+l
~d~td'i_. ar~t
z
~+
~'~,~~.
- : ~,~- ~ . ~.-:
At Cetus, by contrast, via a combination of new procedures, detection
systems and a massive materials-handling capability, it is feasible to
screen thousands of microorganisms daily. If searching for desirable
mutants can~be likened to looking for needles in haystacks, we can scan
many more haystacks than anyone else. Even with average ingenuity we
are sure to find many more needles. The coupling of this unprecedented
mass screening capability with the biological insights of Cetus' scien-
tific team creates an exceptionally powerful combination.
;
'
'
Gy . ;.=5 -:..,
, _. ,~.- ~ ~. ... . . ~:. ,.~- _ ... .:'.. ~ ~~ ` . :... ..:.. .. . _. . - . .' . ;.
+`.~~ a ~~'.t" t 5 -'+«;L' "'~ry°~-~
Ou
fi
t th
th
h
t
i
r
rs
rust was
o ass
e
st
armaceutical industry
p ry in improving
the yields of existing commercial antibiotic cultures. Cetus developed ~~
the capacity to effectively create new strains by mutation and other ~
newer techniques, then to clone and grow large numbers of microorganisms
~
il
mutaneousl = to screen them swiftly for the y potentially most valuable'
strains as they occur; and then to select the most significantly im ,
s
"'
~-proved strains for still further genetic improvement in environments
!:N
From the outset, Cetus has avoided "contract research" relationships
Our purpose has been to build for the future, so we have insisted on a
"piece of the action" in all our client-related programs. Typically, -'
our relationship with client companies has involved two kinds of pay-
ment: a front-end fee to assure continuity of effort and a reward or
"royalty" on the sales arising from new and useful microorganisms
~
.
~
J+~; discovered. Currently, reward credits are accumulating for work suc
~:~,~ cessfully completed.
T'*' ~-~~'_' ',
r`~
_
productive p y- P g
But as our im rovement-b mutation ro ram has been, it has
-~
`~`.,
~'~~~-~: .~.
. ~ ~.~
';}~~~~t+.
resulted in significant yield improvements in the production of major:~°' #
antibiotics '.
controlled for optimal growth. Applying this capability for clients has
In 1973 Dr. Stanley N. Cohen at Stanford and others began developing
techniques for taking DNA from one species of bacteria and inserting it
Z. ~ u , ,~'x_~ ` s+ ~
genetic material of microbes.
Why is the time now so ripe : . .: ._ .. ..
i for a breakthrough in exploiting this kind
of knowledge? Most important, because during the past several years...
science has progressed dramatically in the ability to manipulate the
jy
into the DNA of an entirely different species. This produces a hybrid
;DNA contairiing genes of two entirely different species. This has been
different protein products. Random changes in these organisms, while
,:
~. ._
- had limitations - limitations which no longer need exist. The DNA of
industrial microorganisms codes for a relatively limited number of
.
valuable, pale in significance when compared to what has suddenly been
made possible.
similar manner, biologists can also take certain viruses that infect
only bacteria, insert a set of foreign genes into the viral DNA, and
then infect the bacteria with the new recombinant DNA. ` .6.
done with bacterial plasmid DNA (which also permits the amplification as
well as the heredity transmission of the inserted DNA). In a somewhat
~. .;
1wY. ~_'r.k .~
t*~l
~y f
rF~e
, 1e~~~qjpSS~14i'a:
;~
RV
~~~:~. .~:
W
4.'
Yx`~
~rA1~iY ~

.~ ~
t~'~: ~k:~+~.:::
~ti~s~,:~,
.1s~' ` . _
.,~:. .
J,: ff
=:Y
this is now within our grasp. 4S4
1:
_
This technique, familiarly known as recombinant DNA or "gene stitching,"
has reached the point where it isn't limited to grafting DNA's just
between bacteria. Several laboratories have made recent headlines by
reporting the successful insertion of genes coding for mammalian hor-
mones into bacteria. This breakthrough means that no longer will the
industrial exploitation of microorganisms be limited to getting them to
do better something they already, or almost already do.
human proteins in microorganisms by "stitching" human DNA into the DNA
examples, this means nothing less than producing vast quantities of
..
The future clearly will see many projects in which non-microbial products
are produced using industrial microorganisms. In the most challenging
. r ,
The Future
. . _ . . . - . .. . .. . ~
. ~ ~ .. . =7~fPr
of an appropriate microbe. only recently considered a distant dream,
. ... _ . . , .r.
_ ,.
'- ~ _, .,.~.. .. . . ~ . .. . ~ . . ~' . . ,.-. . . .
~~~ But in the "real world," other simultaneous developments, less romantic
which host may bear no relation to the original organism. This is
this limitation. The genes for the desirable functions should be trans-
ferable to the host organism~best suited to industrial utilization,
the need of producing an "ideal" industrial microorganism - something
which does not yet exist. Where previously the microorganisms, or
"bugs" used to produce useful products, were the natural bugs in which
these capabilities were first discovered, the new technologies relieve
obvious where the oorganism is Homo saPerisf
original i
~~...
F.<.
:
,r.
:-- ., , , - ,,, ,. _ ..~ , 4L;
The challenge is to create the ideal recipient organism - optimized from
many economic and safety points of view. Such an organism, or "biophore
would have great economic utility. (At present, E. coli is widely used f~~?1
[e.g., the cost of nutrients it requires] nor with other production
characteristics.)
. n _. . .. . . .. . .. . - . . . . r.. .. . 'n , . .. r . :i..~..
in basic laboratory research as such a recipient. Indeed, it does have
the advantage of a great backlog of knowledge about its genetics.`';"
Unfortunately, that does not necessarily coincide with economic utility
Currently, Cetus is deeply involved in this field, finding and improving
organisms that have the unique combination of genetic utility and ease
of handling in large-scale fermentation and of producing their gene
productsin readily extractable form.
.,,. . , - _ . . . .._. , ~:. ~
~~ .
4F
a
fqr other projects. With sufficient financing;*it might be more appro-
priate
to carry the autonomous development of a new strain of microor-
ganism to the point where it could be auctioned in a free market for the
most advantageous long-range returns. dMk
±.:. . . _--.. .:.":~t.'~~-'~. ~ . J.:~-'~'- ..-.,. , , .. .:,;.
.. ~,-_- ~.t..,Z~- " ~ - 7
~ ~ ~+v.~
perhaps, but just as important, will be necessary to make possible true=;
return on investment." For many industrial projects Cetus anticipates
It is reasonable to expect proprietary rights to attach to any new
.~.organisms in such a program.
ti
, ..,. .
There remain~many fields to conquer, and Cetus intends to become a major
factor in each. In the field of antibiotics wehave so far opted for-a Q
. '!.pervice to client" relationship, but we may not persist in this pattern jU f-r,
-.{
4_.t~} ~ ~..i,~. .. {17.
-1_
,-,,
~~:~~ ~
~.,...
~nr
!, ~
...i. ::S

,~...,. _ ..
._.. . .~~ ....
New industrial processes for the manufacture of commodity and specialty
chemicals, foodstuffs, and other products could be licensed. This is
the world of biosynthesis: many thoughtful scientists feel that microbes
can tackle virtually any task which can be accomplished by svnthetic
organic chemistry. On more than one occasion the production of a spe-
cific or
anic ch
i
L b
i
bi
l f
g
em
ca
y m
cro
a
ermentation has eclipsed tradi-
tional chemical synthesis on economic grounds. Many advocates believe
that the scope of biosynthesis actually dwarfs non-biotic chemical
synthesis, and they are hopeful that specific applications, such~as the
use of microorganisms to provide vast amounts of food ("single-cell
protein"), will in the not-too-distant future prove them right. The
entire field of microbial-produced insecticides looms as another in
triguing possibility. rµ~
r lCila~37
In certain markets,where marketing would not represent an overwhelming
investment, Cetus might opt to "go it alone," for example, selling and
'~z~"; licensing microorganisms, processes and/or products outri
ht to va
i
g
r
ous
industries.
~~.A~ ~.}
~7~'I .... t , . . . ._..._". .. . .. . . . s . . . ~ .. .. J - , ref ~ . . . .. . _ .. .....~r
Ti~;31,~-tevs.... _:3`? a.~`aw"~Y~itr~~`~.
".. -.. , ~,...... .,.. , :. .: . . . . .. - .... .... . . ...__
'[ xi`.r
+~R ~
V
f~~
~
;~.
final touches needed for commercial utility. It is obvious that Cetus
;
remen
ous accumu
at
on of scientific knowledge is waiting for the
.X
,
'
i q...'.v_ ~
':
Y
A t
d
l
i
y s
to come. , .~ r , ~ ;.«~ ~i~
,.
:i~..,t
.. ll~Y3'e_n {
s,rr
.~
,~;,~
~~-
`
production, will be a prime mover at this new frontier. The challenge,
both scientific and economic, is to identify those programs whose feasibility and utility will
combine to provide the greatest rewards
Each such program will result in an accumulation of know-how and pro
prietary advantage which promises - to us who commit now - a commanding
° position in industrial applications in the life sciences for many years
xr N.
;.}
. .. . . - .. . .. .... ...... . .... 1~ t y ~r w,>t ...,,
These are generalizations and those interested in major participation ~~ ~
y4 ~' with Cetus in future projects will want to hear specifics. Some of the ~
most exciting prospects are in fields that are moving so rapidly, and
;C~. =. _ ~ F a ~Y" ,:.a .t~,`_
,
which has pioneered in the application of sophisticated genetic and
engineering methods for the improvement of microbes for antibiotic
have such large
potential markets, that they require detailed,-up-to
Y the-minute personal presentations by-Cetus scientific and management
~ . r . _.,.
teams. Such presentations will be arranged when appropriate.'s
'... _~. ~ .~~.
L'1R
P:
T!
v.~
?s:~4:c-~2}`':
T"~i~~t~'`.~wF s~ ;ii" i~~"ti ~ ~~~,~e.!~?i~:
s
{
crc P.~,.
t
dks'.xc3YL~~a~.~k'. ":. i~~r~sa.'''.a~:;-
